significantTreatment update
JAK inhibitors (tofacitinib) emerging as potential third-line therapy
Familial Mediterranean Fever →Summary
Multiple independent case series (2024-2025) report that tofacitinib, a JAK1/3 inhibitor, achieves marked suppression of inflammation and sustained remission in FMF patients resistant to both colchicine and IL-1 blockade. Larger controlled studies are needed to establish efficacy and safety.
Related treatments
More from Familial Mediterranean Fever
significantTreatment update
IL-1 blockade established as standard second-line therapy for colchicine-resistant FMF
significantTreatment update
EULAR/PReS 2024 updated management recommendations published
significantNew research
Colchicine resistance mechanisms linked to pyrin inflammasome microtubule independence
incrementalGenetic finding
SAA1 gene polymorphisms identified as independent amyloidosis risk modifier
ID: familial-mediterranean-fever-update-5Type: treatment_updateImpact: significant